New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
AI drives new era of target identification and drug design
- Details
- Category: Business
![Insilico Medicine Insilico Medicine](/images/logo/insilico.png)
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Pfizer announces executive leadership to advance oncology research and development strategy
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Effective today, Chris Boshoff, M.D., PhD, will join Pfizer's Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to
AbbVie and Calibr expand strategic collaboration to advance several preclinical and early-stage clinical assets
- Details
- Category: AbbVie
![AbbVie AbbVie](/images/logo/abbvie.png)
Pfizer announces New England Journal of Medicine publication on Group B Streptococcus (GBS) maternal vaccine candidate
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
DTx’s lead program, DTx-1252 targets the root cause of CMT1A - the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally.
More Pharma News ...
- Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs
- AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
- AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine
- Bayer extends partnership with Peking University to foster pharmaceutical innovation in China
- FDA approves Pfizer's NGENLA™, a long-acting once-weekly treatment for pediatric growth hormone deficiency
- Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations
- FDA accepts Pfizer's application for hemophilia B gene therapy fidanacogene elaparvovec